版本:
中国

BRIEF-Avexis Q4 loss per share $0.92

March 17 Avexis Inc

* Avexis reports topline results from phase 1 trial of avxs-101 in SMA type 1 and fourth quarter and full year 2016 financial and operating results

* Q4 loss per share $0.92

* Q4 earnings per share view $-0.80 -- Thomson Reuters I/B/E/S

* Avexis Inc says no new treatment-related safety or tolerability findings in phase 1 trial of avxs-101

* Avexis Inc says as of January 20, 2017, avxs-101 appeared to have a favorable safety profile and to be generally well tolerated Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐